Loading…
Swiss biopharma selling antifungal and antibacterial hospital drugs, led by Cresemba and Zevtera.
Swiss biopharma selling antifungal and antibacterial hospital drugs, led by Cresemba and Zevtera.
Much of the income comes as royalties and milestone payments from licensing partners that market Cresemba in their regions, plus supply of the drug to them, rather than from its own sales force. Zevtera follows a similar route through regional distributors.
In one line: A small Swiss anti-infectives specialist.
Moat: narrow (IP / patents, regulatory licence). Patent-protected hospital anti-infectives approved and marketed across multiple markets.
Headquarters: Basel, Switzerland · Founded: 2000 · Employees: 189
Size Basilea Pharmaceutica (BSLN.SW) is a Switzerland Health Care company (Pharmaceuticals: Major) with a market value of $1.07B, the 119th largest of 158 Switzerland companies the cockpit tracks. Shares closed at CHF 71.00 on 6 Nov 2026.
Performance Over six months the shares gained 27.5%, against -15.3% for the median peer and +11.6% for the Switzerland market (cap-weighted) — highest of 20 in its peer set.
Growth Revenue grew 4.7% over the last twelve months (peer median +8.2%); the operating margin is 23.9% (peer median 7.0%).
Valuation It trades at 12.4× forward earnings against a peer median of 22.7× (5th cheapest of 14).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -18 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 63.0 points above its cost of capital (5.0% WACC).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 247M | CHF 232M | CHF 209M | CHF 158M | CHF 148M |
| Revenue growth | — | +11% | +32% | +7% | — |
| Gross profit | CHF 217M | CHF 193M | CHF 170M | CHF 131M | CHF 121M |
| EBITDA | CHF 63.6M | CHF 55.3M | CHF 64.7M | CHF 22.7M | CHF 19.4M |
| Net income | CHF 52.4M | CHF 40.2M | CHF 77.6M | CHF 10.5M | CHF 12.1M |
| Free cash flow | CHF 55.3M | CHF 59.5M | CHF 72.7M | CHF 13.4M | CHF 3.92M |
| Capital expenditure | CHF 2.89M | CHF 2.86M | CHF 1.79M | CHF 1.03M | CHF 3.30M |
| Total debt | n/a | CHF 89.2M | CHF 112M | CHF 129M | CHF 187M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Basilea Pharmaceutica BSLN.SW | $1.07B | +27% | +5% | 24% | 12.4× | -5.7% |
| Pfizer PFE | $168B | +14% | +1% | 26% | 10.4× | -4.3% |
| Merck & MRK | $362B | +33% | +5% | 18% | 17.4× | 4.1% |
| Gilead Sciences GILD | $207B | +28% | +7% | 38% | 19.3× | -2.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BSLN.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.1% | -6.0% | 2nd highest of 21 |
| 6-month return | +27.5% | -15.3% | highest of 20 |
| Distance from 52-week high | -6.3% | -34.4% | 2nd highest of 21 |
| Revenue growth (TTM) | +4.7% | +8.2% | 8th lowest of 19 |
| Operating margin | 23.9% | 7.0% | 3rd highest of 19 |
| Forward P/E | 12.4× | 22.7× | 5th cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | -5.7% | 5.3% | 3rd least demanding of 13 |
| Growth delivered (Del g) | +12.7% | +4.2% | 3rd highest of 13 |
| Hurdle (Req g minus delivered) | -18.5 pp | +1.5 pp | least demanding of 13 |
| ROIC minus cost of capital | +63.0 pp | -0.7 pp | highest of 17 |
| EV / EBITDA | 12.3× | 16.9× | 3rd cheapest of 6 |
| Net debt / EBITDA | -1.4× | 0.4× | 2nd least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.07B | +27% | +5% | 24% | 12.4× | -5.7% | +12.7% |
| Viyash Scientific VIYASH.NS | India | $1.07B | +3% | +96% | 13% | 30.3× | 38.6% | +20.4% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.07B | -38% | +117% | -89% | n/a | n/a | n/a |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $1.07B | -15% | +8% | 7% | n/a | 34.1% | -6.0% |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $1.07B | -47% | -55% | -457% | n/a | n/a | n/a |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.08B | -2% | +27% | 4% | 22.7× | 5.0% | +3.5% |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $1.06B | -18% | -27% | -19% | 23.8× | n/a | n/a |
| Renhe Pharmacy 000650.SZ | China | $1.06B | -10% | -7% | 14% | 17.7× | -9.4% | -7.0% |
| BeBetter Med 688759.SS | China | $1.08B | -49% | n/a | n/a | n/a | n/a | n/a |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.09B | -35% | -2% | 13% | 26.5× | 5.5% | +7.7% |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $1.05B | -6% | +8% | 7% | 21.0× | 3.4% | +1.8% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $1.09B | -15% | -4% | 2% | 26.5× | n/a | n/a |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.10B | -29% | +103% | 24% | 10.6× | 8.6% | -4.5% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -13% | +31% | -7% | 4.8× | -6.4% | -7.7% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $1.10B | -51% | +19% | 9% | 49.2× | 13.9% | +4.9% |
| Bio-Thera Solutions 688177.SS | China | $1.10B | -14% | +24% | -44% | n/a | n/a | n/a |
| Blue Jet Healthcare BLUEJET.NS | India | $1.11B | +13% | -28% | 28% | 32.5× | 49.0% | +13.8% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -16% | +7% | 9% | 7.0× | 1.5% | +12.1% |
| SAWAI 4887.T | Japan | $1.03B | -22% | +11% | 9% | 10.9× | n/a | n/a |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.03B | n/a | n/a | n/a | n/a | n/a | n/a |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.11B | -13% | -7% | 3% | n/a | 3.3% | +6.5% |